Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of TepotinibChristian Rolfo, Paul K. Paik, Aurora O’Brate et al.|Clinical Cancer Research|2025Cited by 4
Figure 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of TepotinibChristian Rolfo, Paul K. Paik, Andreas Johne et al.|Unknown|2025Cited by 0
Figure 2 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of TepotinibChristian Rolfo, Paul K. Paik, Aurora O’Brate et al.|Unknown|2025Cited by 0
Table 2 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of TepotinibChristian Rolfo, Paul K. Paik, Aurora O’Brate et al.|Unknown|2025Cited by 0
Data from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of TepotinibChristian Rolfo, Paul K. Paik, Aurora O’Brate et al.|Unknown|2025Cited by 0